戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 own activity for this widely utilized cancer chemotherapeutic drug.
2 dly decreased at 24 h after treatment with a chemotherapeutic drug.
3 zyme activity in single cells treated with a chemotherapeutic drug.
4 mitogenic activity in mice pretreated with a chemotherapeutic drug.
5 t brusatol can be developed into an adjuvant chemotherapeutic drug.
6  decrease in flux following treatment with a chemotherapeutic drug.
7 om dose-limiting toxicity of streptozocin, a chemotherapeutic drug.
8 e more sensitive to doxorubicin, a classical chemotherapeutic drug.
9 confers resistance to ionizing radiation and chemotherapeutic drugs.
10 ereas its deregulation reduces resistance to chemotherapeutic drugs.
11 (I.P./I.V.) injection alone or combined with chemotherapeutic drugs.
12 siRNA knockdown and following treatment with chemotherapeutic drugs.
13 like receptors, reactive oxygen species, and chemotherapeutic drugs.
14 hich is upregulated following treatment with chemotherapeutic drugs.
15  Akt activation and increased sensitivity to chemotherapeutic drugs.
16 igature or embolization, and radiotherapy or chemotherapeutic drugs.
17 ture, improving the delivery and efficacy of chemotherapeutic drugs.
18 f tumor hypoxia and reduction of delivery of chemotherapeutic drugs.
19  on the response of cervical cancer cells to chemotherapeutic drugs.
20 nment which nurtures and protects cells from chemotherapeutic drugs.
21 molar IC50 values, superior to many clinical chemotherapeutic drugs.
22 tase (DHFR), a key target of antibiotics and chemotherapeutic drugs.
23 ncer-cell motility, and higher resistance to chemotherapeutic drugs.
24 lications in tumor growth and treatment with chemotherapeutic drugs.
25 rough apoptosis induction in comparison with chemotherapeutic drugs.
26 s and improve the pharmacokinetic profile of chemotherapeutic drugs.
27 f HER2 confers resistance of cancer cells to chemotherapeutic drugs.
28 is a major dose-limiting side effect of many chemotherapeutic drugs.
29 didate for combination therapy with existing chemotherapeutic drugs.
30  and are still the most widely used forms of chemotherapeutic drugs.
31  PCa tumors and for the targeted delivery of chemotherapeutic drugs.
32 ntly sensitize breast cancer cell to various chemotherapeutic drugs.
33  sensitize cells cross-resistant to multiple chemotherapeutic drugs.
34 ty to cisplatin, one of the most widely used chemotherapeutic drugs.
35  and calcium signaling associated with these chemotherapeutic drugs.
36  Rac activation and increased sensitivity to chemotherapeutic drugs.
37 ity of cells to cell death stimuli including chemotherapeutic drugs.
38 insults to cells, including cytotoxic cancer chemotherapeutic drugs.
39 istance to a variety of chemically unrelated chemotherapeutic drugs.
40 d increased cytotoxicity in combination with chemotherapeutic drugs.
41 ivity of certain types of cancer to standard chemotherapeutic drugs.
42 s and A549 xenografts to cisplatin and other chemotherapeutic drugs.
43 rtmental and intracellular concentrations of chemotherapeutic drugs.
44 s by which brusatol enhances the efficacy of chemotherapeutic drugs.
45 es, and they are often resistant to standard chemotherapeutic drugs.
46 otential adjuvant to improve the efficacy of chemotherapeutic drugs.
47 ith blood transfusions or myeloablation with chemotherapeutic drugs.
48  to structurally- and functionally-divergent chemotherapeutic drugs.
49  and to evaluate and predict the efficacy of chemotherapeutic drugs.
50 nherent drawbacks, there is a search for new chemotherapeutic drugs.
51 te member involved in the cellular efflux of chemotherapeutic drugs.
52 optosis, as well as enhanced accumulation of chemotherapeutic drugs.
53 s associated with systemic administration of chemotherapeutic drugs.
54 llowing real-time monitoring of responses to chemotherapeutic drugs.
55  in cancer cells, and thus sensitise them to chemotherapeutic drugs.
56 dered them sensitive to apoptosis induced by chemotherapeutic drugs.
57 in reduced accessibility to immune cells and chemotherapeutic drugs.
58 fection that is resistant to the majority of chemotherapeutic drugs.
59 ed G1 arrest and induced hypersensitivity to chemotherapeutic drugs.
60  which the HIV-1 reservoir may be limited by chemotherapeutic drugs.
61 ance (MDR) restricts the efficacy of current chemotherapeutic drugs.
62  of the efficacy and toxicity profile of the chemotherapeutic drugs.
63 mediates the cytotoxicity of the anti-cancer chemotherapeutic drug 5-fluorouracil (5-FU) by prolongin
64 ity of cells to the cytotoxic effects of the chemotherapeutic drug 5-fluorouracil, as shown by increa
65 ffectively enhances their sensitivity to the chemotherapeutic drug 5-FU.
66 screens in two bacterial species using three chemotherapeutic drugs: 5-fluorouracil (5-FU), 5-fluoro-
67  P-gp expression and function coincided with chemotherapeutic drug accumulation in brains of WT mice
68 s 31 CAAs that robustly alter response to 56 chemotherapeutic drugs across cell lines representing 17
69                        Vincristine is a core chemotherapeutic drug administered to pediatric acute ly
70  treatment of p53-null cancer cells with the chemotherapeutic drug adriamycin (doxorubicin) induces A
71 nce since this enzyme is currently used as a chemotherapeutic drug against several types of cancer an
72 by paclitaxel, one of the most commonly used chemotherapeutic drugs against various human cancers.
73                         Thus, application of chemotherapeutic drugs along with HO-1 inhibitor may ele
74                                              Chemotherapeutic drugs also activated an alternative cas
75  of both a low-molecular-weight conventional chemotherapeutic drug and a nanotherapeutic agent, leadi
76                                Stratified by chemotherapeutic drug and comorbid pain risk, patients w
77  synergic combinational dosage ratios of the chemotherapeutic drug and the anticancer flavonoid were
78 ffects on cancer cells, several conventional chemotherapeutic drugs and agents used in targeted thera
79  plasma membrane ABC transporters can export chemotherapeutic drugs and confer drug resistance, it is
80 ment with radiation and different classes of chemotherapeutic drugs and describe mechanisms determini
81  endogenous and exogenous chemicals, such as chemotherapeutic drugs and formaldehyde.
82                      The finding that cancer chemotherapeutic drugs and ionizing radiation often prom
83 icity after clinically relevant exposures to chemotherapeutic drugs and ionizing radiation, as well a
84                Moreover, the combined use of chemotherapeutic drugs and metalloproteinase inhibitors
85 cking cholesterol uptake sensitizes cells to chemotherapeutic drugs and potentiates the effect of che
86 inamide enhanced the ROS produced by several chemotherapeutic drugs and produced synergistic cell kil
87  cancer cells as a survival strategy against chemotherapeutic drugs and promotes growth of tumor cell
88 applied to reverse cross-resistance to other chemotherapeutic drugs and restore treatment efficacy.
89 ity, the multi-drug resistance (MDR) to free chemotherapeutic drugs and the deadly metastases of canc
90 eveloped laboratory biosensors for screening chemotherapeutic drugs and to aid in the assessment of D
91  Nrf2 inhibitors to increase the efficacy of chemotherapeutic drugs and to combat chemoresistance, th
92 ated with tumour formation and resistance to chemotherapeutic drugs, and epigenetic modifications are
93 vated by a range of xenochemicals, including chemotherapeutic drugs, and has been suggested to play a
94 f a broad range of bioactive cargos, such as chemotherapeutic drugs, anti-inflammatory agents, antiba
95             There are currently no effective chemotherapeutic drugs approved for the treatment of dif
96 rtion and extension of a ribonucleotide, the chemotherapeutic drug arabinofuranosylcytosine triphosph
97                                      Current chemotherapeutic drugs are effective only transiently be
98 ons, a surgical approach is limited and most chemotherapeutic drugs are ineffective owing to the bloo
99                                Since several chemotherapeutic drugs are known to increase rAAV transd
100                    Systemically administered chemotherapeutic drugs are often ineffective in the trea
101 lementation strategy for assessing potential chemotherapeutic drugs as well as a sensitive and dynami
102 (MTAs), widely used as biological probes and chemotherapeutic drugs, bind directly to tubulin subunit
103 as maintained after DNA damage caused by the chemotherapeutic drug bleomycin.
104 showed markedly increased sensitivity to two chemotherapeutic drugs, bleomycin and etoposide (P < 0.0
105 cancer cells were resistant to cell death by chemotherapeutic drugs but E-cadherin null cells or thos
106 ticity induced by inflammatory mediators and chemotherapeutic drugs but inhibiting this pathway does
107                 Gemcitabine is a widely used chemotherapeutic drug, but limited therapeutic efficacy
108 enhance the resistance of OvCa cells against chemotherapeutic drugs by activating the Akt pathway.
109 ies acquire resistance to apoptosis-inducing chemotherapeutic drugs by downregulating the key effecto
110 may play roles in modulating the efficacy of chemotherapeutic drugs by modulating DNA repair pathways
111 r knowledge, this is the first report that a chemotherapeutic drug can induce HIF-1alpha accumulation
112 cer treatment, recent evidence suggests that chemotherapeutic drugs can promote metastasis through po
113        Convection enhanced delivery (CED) of chemotherapeutic drugs can successfully bypass the blood
114 ith high specificity because many classes of chemotherapeutic drugs can themselves cause myocardial d
115 RAPA), which is used as the antiangiogenesis chemotherapeutic drug, can cutdown the tumor vessels and
116              In this work, we designed a new chemotherapeutic drug candidate against cancer, namely,
117 KK2 knockdown potentiated the effects of the chemotherapeutic drugs carboplatin and PX-866 to reduce
118 role for p21 in cancer cells challenged with chemotherapeutic drugs: cells with either high or low p2
119                                          The chemotherapeutic drug cisplatin (cis-diamminedichloropla
120                                          The chemotherapeutic drug cisplatin is actively transported
121                  As Ctr1 also transports the chemotherapeutic drug cisplatin via direct binding to th
122 epresentative chemical agents, we selected a chemotherapeutic drug (cisplatin) which forms covalent a
123                                         RNAi-chemotherapeutic drug combinations have also been found
124                          By achieving higher chemotherapeutic drug concentrations in target lesions,
125             In mice, DNA damage initiated by chemotherapeutic drug cyclophosphamide activated caspase
126 lowing the induction of neutropenia with the chemotherapeutic drug cyclophosphamide, ExPEC translocat
127 e treated with various concentrations of the chemotherapeutic drugs cyclophosphamide, gemcitabine (GE
128  TMF, sensitivity to six clinically relevant chemotherapeutic drugs (dacarbazine, doxorubicin, paclit
129 when the Pt NPs are loaded in vitro with the chemotherapeutic drug, daunorubicin, and the formulation
130  pre-treatment with N6L efficiently improved chemotherapeutic drug delivery and increased the antitum
131 ultidrug resistance protein 1 (MRP1), before chemotherapeutic drug delivery in vivo with a single loc
132 ow) and potentially enhance co-administrated chemotherapeutic drug delivery.
133 blood brain barrier (BBB) is used to enhance chemotherapeutic drug delivery.
134 l structures available for this enzyme show, chemotherapeutic drug design has centered on stopping th
135 tent oncogene that is a prominent target for chemotherapeutic drug development.
136 tate-specific target for CaP chemopreventive/chemotherapeutic drug development.
137    Since the repeated administration of most chemotherapeutic drugs develops chemoresistance and seve
138                              Given that most chemotherapeutic drugs disrupt ER homeostasis as part of
139 l lines display cross-resistance against the chemotherapeutic drug docetaxel due to MCL1 upregulation
140 ed drug sensitivity to the two commonly used chemotherapeutic drugs, docetaxel and etoposide, judging
141      The highly complex relationship between chemotherapeutic drug dosing and subsequent immunologica
142 e the anticancer activity of the traditional chemotherapeutic drug, DOX, by multiple mechanisms inclu
143 y mild hyperthermia-triggered release of the chemotherapeutic drug doxorubicin (DOX) after hCTMO1 mon
144 fically, PDT in conjugation with widely used chemotherapeutic drug doxorubicin (Dox) proved effective
145 odel, drug eluding beads (DEBs) carrying the chemotherapeutic drug doxorubicin are located at destroy
146  cycle increased MDA cell apoptosis, and the chemotherapeutic drug doxorubicin had a synergistic effe
147 e xenografts, injection of metformin and the chemotherapeutic drug doxorubicin near the tumor is more
148       Here, we report the ability to enhance chemotherapeutic drug doxorubicin penetration using ultr
149 hemosensitizer curcumin and the encapsulated chemotherapeutic drug doxorubicin to maximize a synergis
150        Doxil, a liposomal formulation of the chemotherapeutic drug doxorubicin, is FDA-approved for m
151              In contrast to the conventional chemotherapeutic drug doxorubicin, which induces p53 act
152 st cancer cells to DNA damage induced by the chemotherapeutic drug doxorubicin.
153  allows their subsequent depletion using the chemotherapeutic drug doxorubicin.
154  scaffold acts as a container to encapsulate chemotherapeutic drug doxorubicin.
155 lls were anchorage-independent, resistant to chemotherapeutic drugs doxorubicin and paclitaxel, and r
156 were then subjected to the action of a model chemotherapeutic drug, doxorubicin (DOX), to assess the
157 h s.c. and i.p. models and the presence of a chemotherapeutic drug, doxorubicin, further inhibited MM
158                     We show that E2F1 causes chemotherapeutic drug efflux both in vitro and in vivo v
159      Multidrug resistance-1 (MDR1) acts as a chemotherapeutic drug efflux pump in tumor cells, althou
160 sive, but it has become evident that certain chemotherapeutic drugs elicit immunogenic danger signals
161 ian cells and that certain antibacterial and chemotherapeutic drugs elicit thymine deficiency, a mech
162 eficient cells; treatment of both lines with chemotherapeutic drugs elicited similar intrinsic apopto
163  and physical DNA insults; oxidative stress, chemotherapeutic drugs, environmental pollutants, and su
164  enrichment of CD44(hi) cells exposed to the chemotherapeutic drug epirubicin, which suggests a feed-
165 sive pediatric cancer for which no effective chemotherapeutic drugs exist.
166 ensitizer, and gemcitabine - an FDA approved chemotherapeutic drug for lung cancer chemo-radiotherapy
167          Cisplatin is the most commonly used chemotherapeutic drug for managing solid tumors.
168 have created a large arsenal of targeted and chemotherapeutic drugs for precision medicine.
169 dioisotopes into tumors for internal RIT, or chemotherapeutic drugs for synergistically combined chem
170     Cisplatin is one of the most widely used chemotherapeutic drugs for the treatment of cancer.
171 her therapeutic agents (such as gene, DNA or chemotherapeutic drug) for targeting permeability glycop
172 rattles combined with triggered release of a chemotherapeutic drug from the nanorattles.
173 ployed to investigate the suitability of six chemotherapeutic drugs from the perspective of intratumo
174 s, we found that bacteria can metabolize the chemotherapeutic drug gemcitabine (2',2'-difluorodeoxycy
175 mproved when the virus was combined with the chemotherapeutic drug gemcitabine.
176 ng mice compared to that with the first-line chemotherapeutic drug gemcitabine.
177  enhanced when BMTP-11 was combined with the chemotherapeutic drug gemcitabine.
178                           Using three common chemotherapeutic drugs, gemcitabine (GEM), irinotecan (I
179             Conditioning of tumor cells with chemotherapeutic drug has been shown to enhance the anti
180  of nanocarriers as drug delivery system for chemotherapeutic drugs has become a research hotspot in
181                                              Chemotherapeutic drugs have made significant contributio
182                                  Traditional chemotherapeutic drugs have modest but limited efficacy
183 mergence of resistance to multiple unrelated chemotherapeutic drugs impedes the treatment of several
184 , an anti-microtubule agent, is an effective chemotherapeutic drug in breast cancer.
185 erministic analysis of the success rate of a chemotherapeutic drug in less than 12h.
186 ted resistance to cisplatin, a commonly used chemotherapeutic drug in the treatment of ovarian cancer
187 mbrane, resulting in inadequate retention of chemotherapeutic drugs in cancer cells.
188 ted brain and the ability to locally deliver chemotherapeutic drugs in disease.
189 s been shown to be involved in resistance to chemotherapeutic drugs in many forms of cancers.
190 m that can profile the mechanisms of various chemotherapeutic drugs in minutes.
191 vated Akt activation to confer resistance to chemotherapeutic drugs in Rb-proficient cells, which can
192 ld nanoparticles (AuNPs) functionalized with chemotherapeutic drugs in so-called "complexes" (supramo
193 nografts, and (c) increase biliary uptake of chemotherapeutic drugs in swine.
194 ak is activated normally in response to many chemotherapeutic drugs in the presence of Bax, but remai
195 elodendrimers), for the targeted delivery of chemotherapeutic drugs in the treatment of cancers, are
196             We discovered that resistance to chemotherapeutic drugs in these lines broadly correlates
197 n TACE effectiveness and supports the use of chemotherapeutic drugs in transarterial therapy.
198  STRAP sensitized colorectal cancer cells to chemotherapeutic drugs in vitro and in vivo STRAP deplet
199 reduced the IC50 inhibitory concentration of chemotherapeutic drugs in vitro This MCAM-mediated sensi
200 sensitized GBM cells to several FDA-approved chemotherapeutic drugs including cisplatin, lomustine an
201 ide effects caused by treatment from several chemotherapeutic drugs, including paclitaxel (Taxol(R))
202 hen used in combination with clinically used chemotherapeutic drugs, including temozolomide, reverses
203 been demonstrated to increase sensitivity to chemotherapeutic drugs, including the DNA-crosslinking a
204              We recently showed that several chemotherapeutic drugs induce intratumoral expression of
205                       Because many classical chemotherapeutic drugs induce reactive oxygen species (R
206                         Both irradiation and chemotherapeutic drugs induced upregulation of HMGB1 and
207 were resistant to both serum starvation- and chemotherapeutic drug-induced apoptosis, whereas cells t
208 hannels in the release of nucleotides during chemotherapeutic drug-induced apoptosis.
209 ation of Rad17 disrupts cellular response to chemotherapeutic drug-induced DNA damage and enhances ce
210                           Here, we show that chemotherapeutic drug-induced NF-kappaB activation promo
211 mprehensive review of all published cases of chemotherapeutic drug-induced SCLE.
212 bine and discuss 16 other published cases of chemotherapeutic drug-induced SCLE.
213 tal cancer treated with a combination of the chemotherapeutic drug irinotecan and the monoclonal anti
214  seeded in a 3D extra cellular matrix when a chemotherapeutic drug is flown next to the matrix.
215           Uptake of radiopharmaceuticals and chemotherapeutic drugs is nonuniform at the microscopic
216 fficacy of cancer treatment by radiation and chemotherapeutic drugs is often limited by severe side e
217 success rate of different nanoparticle based chemotherapeutic drugs is presented.
218                     The use of anthracycline chemotherapeutic drugs is restricted owing to potentiall
219                                         Many chemotherapeutic drugs kill only a fraction of cancer ce
220                   Site-specifically released chemotherapeutic drugs killed cancer cells surviving fro
221 ancer strategy alone and in combination with chemotherapeutic drugs known to induce ROS.
222 sotypes, the primary targets for antimitotic chemotherapeutic drugs like taxanes, has implications fo
223 ee delivery of a predetermined amount of the chemotherapeutic drug (liposomal doxorubicin) into the b
224 ugs; in the case of neoplasia, the export of chemotherapeutic drugs may facilitate cellular chemoresi
225 ration and resensitization of tumor cells to chemotherapeutic drugs may hold promise for cancer treat
226 The change in impedance magnitude on flowing chemotherapeutics drugs measured at 12h for drug-suscept
227 by replacing polystyrene particles with pure chemotherapeutic drug nanoparticles of comparable dimens
228 as well as xenobiotics including therapeutic/chemotherapeutic drugs, nutrients, carcinogens, and toxi
229              The effect of many contemporary chemotherapeutic drugs on pregnancy and livebirth is not
230  cyclophosphamide, a bone marrow-suppressive chemotherapeutic drug, on the development and growth of
231 peptide that can be conjugated directly to a chemotherapeutic drug or to nanoparticles for targeted d
232 may be ideal as a combination treatment with chemotherapeutic drugs or other immunotherapies.
233 cancer resistance protein (ABCG2) transports chemotherapeutic drugs out of cells, which makes it a ma
234 flammatory mediator prostaglandin E2 and the chemotherapeutic drug oxaliplatin, modeling the inherent
235 In TNBC cell lines and mouse xenografts, the chemotherapeutic drug paclitaxel increased autocrine TGF
236 el EphA2-targeting agent conjugated with the chemotherapeutic drug paclitaxel.
237 er cells treated with ionizing radiation and chemotherapeutic drug, paclitaxel.
238 ts of Pt(II) complexes, we have modified the chemotherapeutic drug picoplatin with an azide moiety fo
239 ful for cancer treatment in association with chemotherapeutic drugs, possibly allowing a reduction of
240  show that activation of DNA-PKcs and ATM by chemotherapeutic drugs promotes NF-kappaB activity, with
241 differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the asse
242 n of two candidate compounds to the existing chemotherapeutic drug regime: lithium and ibudilast.
243  been widely investigated for spatiotemporal chemotherapeutic drug release applications for cancer ch
244  contribution of bacteria to the response to chemotherapeutic drugs remains poorly understood.
245                               Recurrence and chemotherapeutic drug resistance are two of the most pro
246 regulation of cell division and inducing the chemotherapeutic drug resistance.
247 nifying an important role of CAF exosomes in chemotherapeutic drug resistance.
248              Our present work thus reveals a chemotherapeutic drug-resistant cancer cell vulnerabilit
249 ptive response in cancer and particularly in chemotherapeutic drug-resistant cells.
250 Widely used anti-cancer treatments involving chemotherapeutic drugs result in cancer cell damage due
251  percent inhibitory concentrations (IC50) of chemotherapeutic drugs routinely used to treat breast ca
252 ological processes, disease diagnostics, and chemotherapeutic drug screening.
253 s also affect treatment outcome, and certain chemotherapeutic drugs stimulate cancer-specific immune
254 n pathways that could be targeted by current chemotherapeutic drugs such as cytarabine.
255 ormally reversible, they can be "trapped" by chemotherapeutic drugs such as etoposide and subsequentl
256        Stabilization of this intermediate by chemotherapeutic drugs such as etoposide leads to persis
257 colon cancer cell death after treatment with chemotherapeutic drugs such as etoposide, cisplatin, and
258                            We found that the chemotherapeutic drug susceptibility-associated SNPs are
259         This is especially important for the chemotherapeutic drug Taxol, an important anticancer age
260 umors from 6 of 10 patients treated with the chemotherapeutic drug temozolomide (TMZ) followed an alt
261 ently increased GB cell death induced by the chemotherapeutic drug temozolomide.
262 are generally more resistant to conventional chemotherapeutic drugs than are B-cell ALL blasts.
263           Etoposide (ETO) is a commonly used chemotherapeutic drug that inhibits topoisomerase II act
264                     Etoposide, a widely used chemotherapeutic drug that inhibits topoisomerase II, is
265     Bortezomib, a proteasome inhibitor, is a chemotherapeutic drug that is commonly used to treat a v
266 vestigate A3B expression upon treatment with chemotherapeutic drugs that activate p53, including 5-fl
267 ulations has been demonstrated for classical chemotherapeutic drugs that are mostly hydrophobic, smal
268 s for understanding the mutagenic effects of chemotherapeutic drugs that stabilize the Top1cc.
269 tion and are relevant to the clinical use of chemotherapeutic drugs that target Top2.
270 reduction in P-gp when used with an existing chemotherapeutic drug (that is, doxorubicin).
271 ncer cells significantly more susceptible to chemotherapeutic drugs, that is, cisplatin or etoposide.
272 d a strategy to enhance tumor penetration of chemotherapeutic drugs through use of iRGD peptide (CRGD
273 lgae-derived nanoporous biosilica to deliver chemotherapeutic drugs to cancer cells.
274 minating against devastating cytotoxicity of chemotherapeutic drugs to healthy cells.
275 rnary complex of topoisomerase, DNA, and the chemotherapeutic drug topotecan show important differenc
276                                 A well-known chemotherapeutic drug, topotecan hydrochloride, was used
277 well as in reactive oxygen species (ROS)- or chemotherapeutic drug-treated cell lines.
278 cumulation of endogenous adenosine following chemotherapeutic drug treatment and exposure to hypoxia.
279 ample, ionizing and ultraviolet radiation or chemotherapeutic drug treatment) can activate p53, but a
280 ed mediator of breast cancer senescence upon chemotherapeutic drug treatment.
281 c cytokine secretion and reduced the IC50 of chemotherapeutic drug treatments in AML cells.
282 924 sensitized ovarian cancer cells to other chemotherapeutic drug treatments.
283                                              Chemotherapeutic drugs triggered a positive feedback loo
284 be killed by arsenic trioxide (As(2)O(3)), a chemotherapeutic drug used in the treatment of acute pro
285                      Bleomycin is a powerful chemotherapeutic drug used to treat a variety of cancers
286 -32 before treatment with arabinocytosine, a chemotherapeutic drug used to treat human AML.
287 he risk of relapse, treatment phase, and the chemotherapeutic drugs used concomitantly.
288 ed to the pH, the pulsatile delivery, or the chemotherapeutic drugs used.
289 te a pathway for pain that is induced by the chemotherapeutic drug vincristine sulfate (VCR).
290 AF1 expression is induced in cancer cells by chemotherapeutic drug vincristine that regulates cytopla
291 .05-0.001) potentiated the response to three chemotherapeutic drugs (vincristine, etoposide and metho
292 of tumor-bearing mice were injected with the chemotherapeutic drug, vincristine, alone or in combinat
293 nce of Star-PAP, treatment of cells with the chemotherapeutic drug VP-16 dramatically reduced E6 and
294 f2 rendered SPEC-2 cells more susceptible to chemotherapeutic drugs, whereas it had a limited effect
295 , carcinogenesis, and altered sensitivity to chemotherapeutic drugs, whereas PXR contributes to chemo
296                Oxaliplatin, a platinum-based chemotherapeutic drug, which is used as first-line treat
297 resistance (MDR) after prolonged exposure to chemotherapeutic drugs, which is a severe impediment to
298 nnecessary and irreversible damage caused by chemotherapeutic drugs while still maintaining therapeut
299                   5-Fluorouracil (5-FU) is a chemotherapeutic drug widely used to treat colorectal ca
300 hese results reflect a direct interaction of chemotherapeutic drugs with both the vascular endotheliu

 
Page Top